TSLA
Tesla
-- 429.655 NVDA
NVIDIA
-- 136.950 PLTR
Palantir
-- 79.260 RGTI
Rigetti Computing
-- 11.3100 AMD
Advanced Micro Devices
-- 125.764 
NEWS
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Spero Therapeutics (Nasdaq: SPRO) has published data from its Phase 1 clinical trial assessing the intrapulmonary pharmacokinetics of SPR719, the active moiety of SPR720, in Antimicrobial Agents and Chemotherapy. The study, involving 33 healthy subjects, showed significant lung uptake and enhanced concentrations of SPR719 in epithelial lining fluid (ELF) and alveolar macrophages (AM).
Key findings include:
SPR719 concentrations in ELF and AM were greater than total plasma concentrations
No unexpected safety issues were observed
Results support further investigation of SPR720 as a potential oral treatment for Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD)
The company will present additional data on microbial resistance against SPR719 at IDWeek in October 2024.
Key findings include:
SPR719 concentrations in ELF and AM were greater than total plasma concentrations
No unexpected safety issues were observed
Results support further investigation of SPR720 as a potential oral treatment for Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD)
The company will present additional data on microbial resistance against SPR719 at IDWeek in October 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment